I agree that this site is using cookies. You can find further informations here.
X
LEUFKENS, H. G.
831  results:
Search for persons X
?
1

PMU102 DIFFERENCES IN HEALTH TECHNOLOGY ASSESSMENT RECOMMEN..:

Vreman, R. ; Mantel-Teeuwisse, A.K. ; Hovels, A.M...
Value in Health.  22 (2019)  - p. S725-S726 , 2019
Link: https://doi.org/10.1016/..
 
?
2

PBI75 REVIEW OF ECONOMIC EVALUATIONS FOR GENE THERAPIES:ARE..:

ten Ham, R. ; Leufkens, H.G. ; Klungel, O.H..
Value in Health.  22 (2019)  - p. S431 , 2019
Link: https://doi.org/10.1016/..
 
?
3

PHP369 - CHALLENGES IN ACHIEVING MARKET ACCESS SUCCESS FOR ..:

ten Ham, R.M. ; Hovels, A.M. ; Hoekman, J....
Value in Health.  21 (2018)  - p. S213 , 2018
Link: https://doi.org/10.1016/..
 
?
4

PHP109 - COST OF UNLICENCED AND ORPHAN MEDICINES IN TURKEY,..:

Atikeler, K. ; Goettsch, W. ; Baran, A....
Value in Health.  21 (2018)  - p. S168 , 2018
Link: https://doi.org/10.1016/..
 
?
5

Decision-making on marketing authorization of Advanced Ther..:

de Wilde, S. ; Coppens, D. ; de Bruin, M.L....
Cytotherapy.  19 (2017)  5 - p. S85 , 2017
Link: https://doi.org/10.1016/..
 
?
6

Risk of infections in patients with gout: a population-base..:

Spaetgens, B. ; de Vries, F. ; Driessen, J. H. M....
Scientific Reports.  7 (2017)  1 - p. , 2017
Link: https://doi.org/10.1038/..
 
?
7

PP226—Available and clinically applicable information for r..:

Boer, J.L. ; Beers, E. ; Egberts, T.C...
Clinical Therapeutics.  35 (2013)  8 - p. e89-e90 , 2013
Link: https://doi.org/10.1016/..
 
?
8

PP224—Views of clinical and non-clinical professionals on i..:

Beers, E. ; Egberts, A.C. ; Leufkens, H.G..
Clinical Therapeutics.  35 (2013)  8 - p. e89 , 2013
Link: https://doi.org/10.1016/..
 
?
9

Oc018—The Number Of Included Older People In Recent Pre-Aut..:

Beers, E. ; Moerkerken, D.C. ; Egberts, A.C...
Clinical Therapeutics.  35 (2013)  8 - p. e7-e8 , 2013
Link: https://doi.org/10.1016/..
 
?
10

Fracture rate in patients with myasthenia gravis: the gener..:

Pouwels, S. ; de Boer, A. ; Javaid, M. K....
Osteoporosis International.  24 (2012)  2 - p. 467-476 , 2012
Link: https://doi.org/10.1007/..
 
?
11

Drug Regulatory Systems Must Foster Innovation:

Schellekens, Huub ; Moors, Ellen ; Leufkens, H. G..
Science.  332 (2011)  6026 - p. 174-175 , 2011
Link: https://doi.org/10.1126/..
 
?
12

Drug Regulatory Systems Must Foster Innovation:

SCHELLEKENS, HUUB ; MOORS, ELLEN ; LEUFKENS, H. G.
Science.  332 (2011)  6026 - p. 174-175 , 2011
Link: https://www.jstor.org/st..
 
?
13

Use of proton pump inhibitors and risk of hip/femur fractur..:

Pouwels, S. ; Lalmohamed, A. ; Souverein, P....
Osteoporosis International.  22 (2010)  3 - p. 903-910 , 2010
Link: https://doi.org/10.1007/..
 
?
14

Use of antidepressants and risk of osteoporotic and non-ost..:

Souverein, P.C. ; Bazelier, M.T. ; Lalmohamed, A....
Bone.  47 (2010)  - p. S189 , 2010
Link: https://doi.org/10.1016/..
 
?
15

Incidence and determinants of antidepressant drug use in mi..:

Rahimtoola, H. ; Buurma, H. ; Tijssen, C.C...
International Clinical Psychopharmacology.  18 (2003)  6 - p. 331-339 , 2003
Link: https://doi.org/10.1097/..
 
1-15